How I treat newly diagnosed chronic phase CML

Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

The progress made in the understanding of chronic myeloid leukemia (CML) since the recognition of a common chromosomal abnormality to the introduction of ever more effective tyrosine kinase inhibitors is unprecedented in cancer. The expected survival for patients diagnosed with CML today, if properly managed, is probably similar to that of the general population. When managing patients with CML the goal is to achieve the best long-term outcome and we should base the treatment decisions on the data available. The results from cytogenetic and molecular analyses have to be interpreted judiciously and all available treatment options integrated into the treatment plan properly. The availability of several treatment options in CML is an asset, but the temptation of rapid succession of treatment changes because of perceived suboptimal response or for adverse events that could be managed needs to be avoided. Any decision to change therapy needs to weigh the expected long-term outcome with the current option versus the true expectations with any new option, particularly as it relates to irreversible outcomes, such as transformation to blast phase and death. In this manuscript, we discuss the treatment approach that has helped us manage successfully a large CML population.

Original languageEnglish (US)
Pages (from-to)1390-1397
Number of pages8
JournalBlood
Volume120
Issue number7
DOIs
StatePublished - Aug 16 2012
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Protein-Tyrosine Kinases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Availability
Therapeutics
Blast Crisis
Cytogenetic Analysis
Chromosome Aberrations
Population
Survival

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

How I treat newly diagnosed chronic phase CML. / Cortes, Jorge; Kantarjian, Hagop.

In: Blood, Vol. 120, No. 7, 16.08.2012, p. 1390-1397.

Research output: Contribution to journalArticle

Cortes, Jorge ; Kantarjian, Hagop. / How I treat newly diagnosed chronic phase CML. In: Blood. 2012 ; Vol. 120, No. 7. pp. 1390-1397.
@article{8496d813872b4de5b4936334523c71ee,
title = "How I treat newly diagnosed chronic phase CML",
abstract = "The progress made in the understanding of chronic myeloid leukemia (CML) since the recognition of a common chromosomal abnormality to the introduction of ever more effective tyrosine kinase inhibitors is unprecedented in cancer. The expected survival for patients diagnosed with CML today, if properly managed, is probably similar to that of the general population. When managing patients with CML the goal is to achieve the best long-term outcome and we should base the treatment decisions on the data available. The results from cytogenetic and molecular analyses have to be interpreted judiciously and all available treatment options integrated into the treatment plan properly. The availability of several treatment options in CML is an asset, but the temptation of rapid succession of treatment changes because of perceived suboptimal response or for adverse events that could be managed needs to be avoided. Any decision to change therapy needs to weigh the expected long-term outcome with the current option versus the true expectations with any new option, particularly as it relates to irreversible outcomes, such as transformation to blast phase and death. In this manuscript, we discuss the treatment approach that has helped us manage successfully a large CML population.",
author = "Jorge Cortes and Hagop Kantarjian",
year = "2012",
month = "8",
day = "16",
doi = "10.1182/blood-2012-03-378919",
language = "English (US)",
volume = "120",
pages = "1390--1397",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - How I treat newly diagnosed chronic phase CML

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2012/8/16

Y1 - 2012/8/16

N2 - The progress made in the understanding of chronic myeloid leukemia (CML) since the recognition of a common chromosomal abnormality to the introduction of ever more effective tyrosine kinase inhibitors is unprecedented in cancer. The expected survival for patients diagnosed with CML today, if properly managed, is probably similar to that of the general population. When managing patients with CML the goal is to achieve the best long-term outcome and we should base the treatment decisions on the data available. The results from cytogenetic and molecular analyses have to be interpreted judiciously and all available treatment options integrated into the treatment plan properly. The availability of several treatment options in CML is an asset, but the temptation of rapid succession of treatment changes because of perceived suboptimal response or for adverse events that could be managed needs to be avoided. Any decision to change therapy needs to weigh the expected long-term outcome with the current option versus the true expectations with any new option, particularly as it relates to irreversible outcomes, such as transformation to blast phase and death. In this manuscript, we discuss the treatment approach that has helped us manage successfully a large CML population.

AB - The progress made in the understanding of chronic myeloid leukemia (CML) since the recognition of a common chromosomal abnormality to the introduction of ever more effective tyrosine kinase inhibitors is unprecedented in cancer. The expected survival for patients diagnosed with CML today, if properly managed, is probably similar to that of the general population. When managing patients with CML the goal is to achieve the best long-term outcome and we should base the treatment decisions on the data available. The results from cytogenetic and molecular analyses have to be interpreted judiciously and all available treatment options integrated into the treatment plan properly. The availability of several treatment options in CML is an asset, but the temptation of rapid succession of treatment changes because of perceived suboptimal response or for adverse events that could be managed needs to be avoided. Any decision to change therapy needs to weigh the expected long-term outcome with the current option versus the true expectations with any new option, particularly as it relates to irreversible outcomes, such as transformation to blast phase and death. In this manuscript, we discuss the treatment approach that has helped us manage successfully a large CML population.

UR - http://www.scopus.com/inward/record.url?scp=84865192326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865192326&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-03-378919

DO - 10.1182/blood-2012-03-378919

M3 - Article

C2 - 22613793

AN - SCOPUS:84865192326

VL - 120

SP - 1390

EP - 1397

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -